Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
about
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Amifostine enhances the antioxidant and hepatoprotective effects of UW and HTK preservation solutions.Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance.Sustained-release microspheres of amifostine for improved radio-protection, patient compliance, and reduced side effects.
P2860
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@ast
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@en
type
label
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@ast
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@en
prefLabel
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@ast
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@en
P2093
P2860
P1476
Clinical pharmacokinetics of a ...... patients with medulloblastoma.
@en
P2093
Amar Gajjar
Clinton F Stewart
John C Panetta
M Fatih Okcu
Trevor McKibbin
P2860
P304
P356
10.1158/1078-0432.CCR-09-1997
P407
P577
2010-01-26T00:00:00Z